News | Cardiac Imaging | October 11, 2022

Identifying Patients with Sarcoidosis at Risk for Bad Cardiac Outcomes

Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes.

Chetan Shenoy, MBBS, MS


October 11, 2022 — Researchers from the University of Minnesota Medical School found that patients with certain features on magnetic resonance imaging (MRI) of the heart are at much higher risk for cardiac sarcoidosis-related adverse outcomes. These patients may benefit from an implantable cardioverter defibrillator. Meanwhile, other features identified patients at very low risk who might not benefit from the device. These findings were published recently in JAMA Cardiology

Cardiac sarcoidosis is a rare inflammatory heart disease that can result in rhythm disturbances and heart failure. Sarcoidosis is estimated to affect approximately 200,000 Americans.  

“Late gadolinium enhancement on cardiovascular magnetic resonance imaging is often used to diagnose cardiac sarcoidosis. Our research shows that not all patients with late gadolinium enhancement on cardiac MRI  have the same risk of adverse outcomes, particularly ventricular arrhythmias,” said Chetan Shenoy, MBBS, MS, an associate professor of medicine at the University of Minnesota Medical School and the lead author of the study. “We believe our findings will help optimize the clinical care of patients with suspected cardiac sarcoidosis, and consequently, lead to better outcomes.” 

In this largest study yet of suspected cardiac sarcoidosis investigated by cardiac MRI, the researchers studied 504 patients. The MRI features were based on the research team’s previously published study that described features of cardiac damage in the hearts of patients with cardiac sarcoidosis who had suddenly died or needed heart transplantation. 

Researchers note that these findings should be replicated in other, more diverse, cohorts. Whether clinical management guided by these cardiac MRI features improves outcomes in patients with suspected cardiac sarcoidosis should be prospectively tested in a randomized trial. 

For more information: www.med.umn.edu 

Related Cardiac Sarcoidosis Content: 

VIDEO: Utilization of PET For Evaluation of Cardiac Sarcoidosis 

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis 

New PET-CT Scan Improves Detection in Rare Cardiac Condition 

25 Most Impactful Nuclear Cardiology Articles 

Recent Advances in Cardiac Nuclear Imaging Technology 


Related Content

News | Cardiac Imaging

March 18, 2026 — Circle Cardiovascular Imaging (Circle CVI) has announced the expansion of its cvi42 cardiovascular ...

Home March 20, 2026
Home
News | Cardiac Imaging

March 19, 2026 — Heart disease is the leading cause of adult death worldwide, making cardiovascular disease diagnosis ...

Home March 20, 2026
Home
News | Cardiac Imaging

March 16, 2026 — The American Society for Preventive Cardiology (ASPC) will host its 2026 Virtual Imaging Symposium, a ...

Home March 17, 2026
Home
Feature | Cardiac Imaging

Sponsored Content — According to the American Heart Association, cardiovascular disease is the leading cause of death in ...

Home March 13, 2026
Home
News | Cardiac Imaging

March 6, 2026 — Building on its leadership in cardiac MR, Philips has received FDA 510(k) clearance for SmartHeart, an ...

Home March 09, 2026
Home
News | Cardiac Imaging

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Home February 26, 2026
Home
News | Cardiac Imaging

Feb. 13, 2026 — Conavi Medical Corp. recently highlighted the publication of new peer-reviewed research titled “Deep ...

Home February 16, 2026
Home
News | Cardiac Imaging

Jan. 27. 2026 — Circle Cardiovascular Imaging Inc. has announced the release of cvi42 v6.4, the latest version of its ...

Home January 28, 2026
Home
News | Cardiac Imaging

Jan. 6, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced FDA clearance to expand its ...

Home January 16, 2026
Home
News | Cardiac Imaging

Jan. 12, 2026 — YorLabs, Inc., a medical technology company providing next-generation intracardiac imaging solutions for ...

Home January 13, 2026
Home
Subscribe Now